Monoclonal Anti-Human Immunodeficiency Virus Type 1 (HIV-1) Tat Protein, Clone 11H6H1 (produced *in vitro*)

Catalog No. HRP-20069

For research use only. Not for use in humans.

Contributor and Manufacturer:
Creative Biolabs, Inc., Shirley, New York, USA

Product Description:
Creative Biolabs Catalog No. PABL-568CQ-LowE
Antibody Class: IgG1κ
Mouse monoclonal antibody prepared against the Tat protein of human immunodeficiency virus type 1 (HIV-1; UniProt: P04591) was produced from the expression vectors by transient transfection and expression in mammalian cells with chemically defined culture media, purified by affinity chromatography, ultrafiltrated and sterile filtered.[1] This antibody is specific for the N-terminal region of Tat.

Tat is one of the first proteins to be expressed after HIV infection occurs. It has been suggested that Tat antagonists may be of use in the treatment of HIV infections.[2]

Material Provided:
Each vial of HRP-20069 contains approximately 100 µL of purified monoclonal antibody in phosphate-buffered saline (PBS). The concentration, expressed as milligrams per milliliter, is shown on the Certificate of Analysis.

Packaging/Storage:
HRP-20069 was packaged aseptically in screw-capped plastic vials and is provided frozen on dry ice. The product should be stored at -20°C or colder immediately upon arrival. Freeze-thaw cycles should be avoided.

Functional Activity:
HRP-20069 recognizes the Tat protein of HIV-1 and was shown to be reactive in ELISA assay.[1]

Citation:
Acknowledgment for publications should read "The following reagent was obtained through the NIH HIV Reagent Program, NIAID, NIH: Monoclonal Anti-Human Immunodeficiency Virus Type 1 (HIV-1) Tat Protein, Clone 11H6H1 (produced *in vitro*), HRP-20069, contributed by Creative Biolabs, Inc."

Biosafety Level: 1
Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 6th ed. Washington, DC: U.S. Government Printing Office, 2020; see www.cdc.gov/biosafety/publications/bmbl5/index.htm.

Disclaimers:
You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the NIH HIV Reagent Program Material Transfer Agreement (MTA). The MTA is available on our Web site at www.hivreagentprogram.org.

While the NIH HIV Reagent Program uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to the NIH HIV Reagent Program are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:
This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:
1. Young, S., Personal Communication.
2. Rice, A. P. "The HIV-1 Tat Protein: Mechanism of Action and Target for HIV-1 Cure Strategies." Curr. Pharm. Des. 23 (2017): 4098-4102. PubMed: 28677507.

ATCC® is a trademark of the American Type Culture Collection.

Support Provided by NIAID

NIH HIV Reagent Program
www.hivreagentprogram.org
E-mail: contact@HIVReagentProgram.org
Tel: **888-487-0727** | Fax: **703-365-2898**

© 2022 American Type Culture Collection (ATCC)
All rights reserved.